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Background-—The results of the recently published randomized SIMPLE trial question the role of routine intraoperative
deﬁbrillation testing. However, testing is still recommended during implantation of the entirely subcutaneous implantable
cardioverter-deﬁbrillator (S-ICD) system. To address the question of whether deﬁbrillation testing in S-ICD systems is still
necessary, we analyzed the data of a large, standard-of-care prospective single-center S-ICD registry.
Methods and Results-—In the present study, 102 consecutive patients received an S-ICD for primary (n=50) or secondary
prevention (n=52). Deﬁbrillation testing was performed in all except 4 patients. In 74 (75%; 95% CI 0.66–0.83) of 98 patients,
ventricular ﬁbrillation was effectively terminated by the ﬁrst programmed internal shock. In 24 (25%; 95% CI 0.22–0.44) of 98
patients, the ﬁrst internal shock was ineffective and further internal or external shock deliveries were required. In these patients,
programming to reversed shock polarity (n=14) or repositioning of the sensing lead (n=1) or the pulse generator (n=5) led to
successful deﬁbrillation. In 4 patients, a safety margin of <10 J was not attained. Nevertheless, in these 4 patients, ventricular
arrhythmias were effectively terminated with an internal 80-J shock.
Conclusions-—Although it has been shown that deﬁbrillation testing is not necessary in transvenous ICD systems, it seems
particular important for S-ICD systems, because in nearly 25% of the cases the primary intraoperative test was not successful. In
most cases, a successful deﬁbrillation could be achieved by changing shock polarity or by optimizing the shock vector caused by
the pulse generator or lead repositioning. ( J Am Heart Assoc. 2016;5:e003181 doi: 10.1161/JAHA.115.003181)
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T he implantable-cardioverter deﬁbrillator (ICD) is anestablished therapy for primary and secondary prevention
of sudden cardiac death.1,2 The totally subcutaneous implan-
table deﬁbrillator (S-ICD; Boston Scientiﬁc) has been intro-
duced as a new alternative to the conventional transvenous
deﬁbrillator system. The obvious advantages of this system are
marketed as a minimization of lead complications and systemic
infections. This innovative system can particularly be consid-
ered in patients with congenital heart disease,3 other rare
entities impeding transvenous lead implantation,4 or electrical
heart disease.5,6 The early results of the worldwide Evaluation
oF FactORs ImpacTing CLinical Outcome and Cost Effective-
neSS (EFFORTLESS) registry suggested an appropriate system
performance. Occurrence of arrhythmic events and inappropri-
ate shocks resembled those reported for conventional transve-
nous ICD systems.7 These results were conﬁrmed in the 2-year
follow-up of the same cohort.8 Common problems in the S-ICD
patient population requiring surgical revision or changes in
device settings are lead migration, inappropriate sensing due to
muscular noise, and T-wave oversensing.9–13 Ineffective shocks
have also been described previously.14
The results of the recently published Shockless IMPLant
Evaluation (SIMPLE) trial question the value of perioperative
deﬁbrillation testing in individuals undergoing ICD implanta-
tion.15 In this single-blinded, randomized, multicenter nonin-
feriority trial, routine deﬁbrillation testing at the time of
implantation did not improve shock efﬁcacy or reduce
arrhythmic death.15 The lack of long-term experience with
the S-ICD system and the described cases of ineffective
shock deliveries underline the necessity of intraoperative
deﬁbrillation testing in S-ICD recipients. Thorough data on
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intraoperative deﬁbrillation testing in these patients are not
yet available. Thus, in the present study, the single-center
experience of 102 consecutive patients undergoing intraop-
erative deﬁbrillation tests was systematically evaluated.
Methods
The study conforms to the Declaration of Helsinki and later
amendments and was approved by an institutional review
board. Patients gave informed consent for S-ICD implantation
and testing. Between July 2010 and June 2015, 102 S-ICD
systems were implanted at our institution. These consecutive
patients were retrospectively analyzed. Patient baseline
characteristics are summarized in Table 1. The left paraster-
nal position of the shock coil with the pulse generator
positioned over the sixth rib in the left mid-axillary line was
recognized as the optimal conﬁguration.16 All patients
underwent a standardized intraoperative deﬁbrillation test.
Before induction of ventricular ﬁbrillation by using a DC burst
for 4 seconds, the detection rate was lowered to a minimal
value of 170 bpm. The ﬁrst shock energy was programmed to
65 J, resulting in a safety margin of at least 15 J. In case of an
ineffective ﬁrst shock delivery, the second shock energy was
programmed to 80 J in reversed polarity. An ineffective
second shock delivery would have required external deﬁbril-
lation. An ineffective ﬁrst shock required further tests in either
reverse polarity or after repositioning of the subcutaneous
lead and/or the pulse generator. Data are presented as
percentages including 95% CI. Left ventricular ejection
fraction (LVEF) and body mass index (BMI) are presented as
meanSD.
Results
Induction of Ventricular Fibrillation and
Effectiveness of First Shock Delivery
One hundred of 102 consecutive S-ICD recipients underwent
intraoperative deﬁbrillation testing. In 1 patient, deﬁbrillation
test not done because of ﬁbrotic adhesions on a dialysis
catheter, while another patient was not tested because of
severe comorbidities. Two of these 100 patients were not
inducible despite numerous attempts with DC bursts of
different lengths.
In 74 (75%; 95% CI 66–83%) of 98 patients, ventricular
ﬁbrillation was effectively terminated by the ﬁrst programmed
internal shock. In 24 (25%; 95% CI 22–44%) of 98 patients, the
ﬁrst internal shock was ineffective and further internal or
external shock deliveries were required (Figures 1 and 2A).
Ineffective Shock Delivery
In 14 of 24 patients with ineffective ﬁrst shock of 65 J, further
deﬁbrillation with reversed polarity and the same energy was
effective (Table 2). Therefore, the ﬁrst shock was pro-
grammed with reversed polarity in these patients. In 6
patients with ineffective ﬁrst shock of 65 J, further deﬁbril-
lation attempts with reversed polarity and maximum energy
were not effective. These patients underwent a ﬂuoroscopic
examination in which a potential for improvement of the
shock vector was diagnosed. Therefore, repositioning of the
sensing lead and/or the pulse generator under ﬂuoroscopic
control was performed. In 4 of these patients, the can was
moved to a more cranial position (Figure 2B), while in 1
patient, the can was positioned more caudal. In 1 additional
patient, the sensing lead was moved to a right parasternal
position. In 4 additional patients with ineffective ﬁrst shock,
further attempts with reversed polarity and increased shock
energy (either 70 or 80 J) effectively terminated ventricular
ﬁbrillation. In 2 of these patients, ventricular ﬁbrillation could
not be further induced for a second test. Therefore, further
intraoperative tests were impeded. In the other 2 patients,
ﬂuoroscopic examination revealed an ideal position of the
sensing lead and the pulse generator. Therefore, a decreased
safety margin of <10 was accepted in these 4 patients.
Discussion
In the present study, in a signiﬁcant proportion of S-ICD
recipients who underwent routine intraoperative deﬁbrillation
testing, the ﬁrst shock of 65 J did not effectively terminate
ventricular ﬁbrillation. In most cases, either programming of a
reversed shock polarity or repositioning of the sensing lead
solved this problem and resulted in successful deﬁbrillation.
Table 1. Baseline Characteristics
Age, y 4116
Male sex, n 68 (67%)
Coronary artery disease, n 13 (13%)
Dilated cardiomyopathy, n 16 (15%)
Electrical heart disease, n 21 (20%)
Hypertrophic cardiomyopathy, n 21 (20%)
Congenital heart disease, n 6 (6%)
Valvular heart disease, n 8 (8%)
Idiopathic ventricular fibrillation, n 9 (9%)
Other, n 9 (9%)
Primary prevention, n 50 (49%)
Secondary prevention, n 52 (51%)
LVEF, % 5214%
BMI, kg/m2 26.35.1
BMI indicates body mass index; LVEF, left ventricular ejection fraction.
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Figure 1. Representative example of an ineffective shock delivery during intra-operative deﬁbrillation
test: 2 ineffective internal shocks. Ventricular ﬁbrillation was subsequently terminated by external
deﬁbrillation.
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Figure 2. A, Another ineffective internal shock in the same patient after programming of reversed
polarity without altering the position of the pulse generator and subsequent external deﬁbrillation. B,
Example of an effective internal shock delivery during deﬁbrillation testing in the same patient after
repositioning of the pulse generator in a more cranial position.
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However, in a small percentage of these patients, a reduced
safety margin of <10 J had to be accepted. With regard to the
recently published results of the SIMPLE trial that questions
the clinical value of routine deﬁbrillation testing in patients
receiving conventional transvenous ICD,15 the results of the
present study underline that deﬁbrillation tests are currently
necessary to evaluate system functionality.
Deﬁbrillation Testing in Patients With
Transvenous ICD Systems
Routine deﬁbrillation tests in patients with the use of modern
conventional ICD systems are almost always effective in the
ﬁrst programmed shock conﬁguration.17 In a study that
included 1530 ICD recipients, only 3.9% did not meet the 10J
safety margin criterion. After programming of reversed
shocking polarity, lead repositioning, or addition of a subcu-
taneous array, a 10-J safety margin could be achieved in all
patients.17
In the SIMPLE study, ICD implantation without deﬁbrillation
testing was not inferior to intraoperative deﬁbrillation testing
regarding long-term efﬁcacy of the ICD or total mortality.
These results were judged as rather robust by the authors and
could simplify the implantation procedure of transvenous ICD
systems in the future. Of note, an increased mortality rate
compared with other ICD studies was described in the SIMPLE
population.18,19 This aspect was attributed to the fact that the
patient population in the SIMPLE study presented many
comorbidities. However, small patient groups that might have
a higher risk for ineffective shock deliveries such as patients
with hypertrophic cardiomyopathy might not be sufﬁciently
encompassed in this study. The results of the NO Regular
Deﬁbrillation testing In Cardioverter Deﬁbrillator Implantation
(NORDIC-ICD) trial, also randomized, further underlined that
intraoperative deﬁbrillation testing during routine left-sided
ICD implantation does not improve deﬁbrillation efﬁcacy.20,21
Ineffective Shock Deliveries of the S-ICD System
Ineffective shock deliveries have been described in the
literature. These episodes can also occur in patients who
undergo successful intraoperative deﬁbrillation testing.14 The
cited cases mostly resulted in subsequent system explanta-
tion and implantation of a transvenous ICD. In case of
deﬁbrillation threshold problems, comparable positions of the
subcutaneous lead—as described in the present study—have
been suggested previouslye.22 These attempts to improve the
shock vector can only be minimal because complex reposi-
tioning manoeuvers are impeded by the rather strict localiza-
tion of the S-ICD system. Further, other possible interventions
to improve shock efﬁcacy that are available in transvenous
ICD systems, such as implantation of a subcutaneous array,
cannot be used.
Limitations
The present study is a single-center experience of intraoper-
ative deﬁbrillation testing of S-ICD systems with a small
sample size compared with former multicenter trials with
transvenous ICD systems. Of note, the patient population
fundamentally differs from patients in former trials because in
the present study mostly young patients with channelopathies
and patients who underwent extraction of transvenous ICD
systems as a results of infections received S-ICD systems,
while the majority of ICD recipients in previous studies
consists of older patients with ischemic or nonischemic heart
disease. Further, predictors of successful termination of
ventricular ﬁbrillation could not be identiﬁed because of the
limited sample size. This aspect represents an important area
of future research.
Conclusion
The results of the present study underline that in a signiﬁcant
proportion of S-ICD recipients ineffective shock deliveries may
occur during routine intraoperative deﬁbrillation testing. In the
majority of these cases, the shock vector could be improved
by programming a reversed shock polarity or repositioning of
the sensing lead or the pulse generator. These results imply
that ineffective shock deliveries are more common in S-ICD
patients than in patients with conventional transvenous ICDs.
In addition, revision of programmed shock polarity of
repositioning of the lead or pulse generator is often necessary
to ensure adequate system functionality. Therefore, the
recently published study data most likely cannot be directly
transferred to S-ICD recipients and patients who receive these
innovative devices should still be tested during the implan-
tation procedure.
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Table 2. Results of Intraoperative Deﬁbrillation Testing
(n=98)
Successful first defibrillation test 74 (75%)
Successful test with reversed shock polarity 14 (15%)
Successful test after lead repositioning 1 (1%)
Successful test after pulse generator repositioning 5 (5%)
Safety margin <10 J 4 (4%)
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